Top

Drugs

Published in:

01-10-2002 | Adis New Drug Profile

Rosuvastatin

Authors: Christopher I. Carswell, Greg L. Plosker, Blair Jarvis

Published in: Drugs | Issue 14/2002

Abstract

▴ Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively metabolised and has a low propensity for drug interactions.
▴ In well designed trials of between 6 and 52 weeks’ duration, rosuvastatin was superior to atorvastatin, simvastatin and pravastatin in improving the lipid profile of patients with hypercholesterolaemia. In a 1-year dose-titration study, rosuvastatin 13.4mg daily (mean dose) allowed more patients to achieve US National Cholesterol Education Program (Adult Treatment panel II)[NCEP] target low-density lipoprotein (LDL)-cholesterol levels than atorvastatin 20.8mg daily (98 vs 87%) with the difference most marked in high-risk patients (97 vs 61%).
▴ Similarly, when compared with pravastatin and simvastatin 20 mg/day in a further 1-year trial, 88% of rosuvastatin recipients [9.5 and 13.8 mg/day (mean doses)] achieved NCEP target serum LDL-cholesterol levels compared with 60 and 73% of pravastatin and simvastatin recipients, respectively, with the difference more marked in high-risk patients.
▴ In further clinical trials, rosuvastatin improved the lipid profile of patients with heterozygous or homozygous familial hypercholesterolaemia, hypertriglyceridaemia or mixed dyslipidaemias.
▴ Rosuvastatin was well tolerated in clinical trials of up to 1 years’ duration.

American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2002

McKenney JM. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. PharmacoEconomics 1998; 14 Suppl. 3: 19–28CrossRef

Amsterdam EA, Deedwania PC. A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. Am J Med 1998 Jul 6; 105 Suppl. 1A: 69–74CrossRef

Shepherd J, Cobbe S, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 November 16; 333(20): 1301–7PubMedCrossRef

Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 November 19; 344: 1383–9

Assman G, Cullen P, Jossa F, et al. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease: a worldwide view. Arterioscler Thromb Vasc Biol 1999 Aug; 19: 1819–24CrossRef

Wood D, De BG, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Atherosclerosis 1998 Oct; 140: 199–270PubMedCrossRef

Expert Panel on Detection E and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program. JAMA2001 May 16; 285(19): 2486–97CrossRef

Chong PH, Bachenheimer BS. Current,new and future treatments in dyslipidaemia and atherosclerosis. Drugs 2000 July; 60: 55–93PubMedCrossRef

10.

Hatch GM. Rosuvastatin. Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs 2000; 2(3): 270–3

11.

Graul A, Castaner J. ZD-4522. Hypolipidemic, HMG-CoA reductase inhibitor. Drugs Future 1999; 24(5): 511–3

12.

The LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 November 5; 339(19): 1349–57CrossRef

13.

Sacks F, Pfeffer M, Moye L. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 October 3; 335(14): 1001–9PubMedCrossRef

14.

Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999 Aug 12; 341(7): 498–511PubMedCrossRef

15.

McTaggart F, Buckett L, Davidson R. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitor. Am J Cardiol 2001 Mar 8; 87 Suppl. 5a: 28B–32BPubMedCrossRef

16.

Watanabe M, Koike H, Ishiba T, et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-meth-anesulfonyl pyrrole-substituted 3,5-dihydroxy-6-hepten-oates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 1997; 5(2): 437–44PubMedCrossRef

17.

Cameron NE, Smith GJ, McTaggart F, et al. Effects of treatment with the statin, ZD4522, on peripheral nerve function and perfusion in diabetic rats [abstract]. Diabetologia 2000 Aug; 43 Suppl. 1: 50

18.

Prass R, Caslake M, Packard CJ, et al. Rosuvastatin enhances lipid fluidity in atherogenic apoB-containing lipoproteins. [poster] Presented at the European Atherosclerosis Society, 73rd EAS Congress, Slazburg, Austria, 2002 7–10 July

19.

Brown CDA, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Poster and abstract presented at the European Atherosclerosis Society, 72nd EAS Congress; 2001 May 20–23; Glasgow, UK

20.

Stalker T, Lefer A, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001; 133: 406–12PubMedCrossRef

21.

Warwick MJ, Dane AL, Raza A, et al. Pharmacokinetic and safety profile for the new HMG-CoA reductase inhibitor ZD4522 (single and multiple doses) [abstract]. Can J Cardiol 2000 Sep; 16 Suppl. F: 196F

22.

Martin PD, Dane AL, Nwose D, et al. Effects of age and gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. Clin Pharmacol Ther 2001 Feb; 69 Suppl.: P56

23.

Martin PD, Mitchell PD, Schneck DW. Pharmacodynamics effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after am and pm administration in healthy subjects [abstract]. J Clin Pharmacol 2000 Sep; 40: 1056

24.

Martin PD, Dane AL, Schneck DW, et al. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000 Sep; 40: 1056

25.

McCormick AD, McKillop D, Butters CJ, et al. ZD4522-an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000 Sep; 40: 1055

26.

Simonson SG, Martin PD, Mitchell PD, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in hepatically impaired subjects. Clin Pharmacol Ther 2001 Feb; 69 Suppl.): 86

27.

Kemp J, Martin P, Olise MD. Coadministration of rosuvastatin does not alter the pharmacokinetics of digoxin. Pharmacotherapy 2001 Oct; 21(10): 1255

28.

Cooper KJ, Martin PD, Dane AL, et al. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001; 89 Suppl. 1: 75 Abstract no. 286

29.

Martin PD, Cooper KJ, Dane AL, et al. Ketoconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001; 89 Suppl. 1: Abstract no. 286

30.

Cooper KJ, Martin PD, Dane AL, et al. Fluconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin. Pharmacol Toxicol 2001; 89 (Suppl. 1): Abstract no. 288

31.

Martin PD, Cooper KJ, Dane AL, et al. Itraconazole produces modest increases in rosuvastatin plasma concentrations. Pharmacol Toxicol 2001; 89 (Suppl. 1): Abstract no. 297

32.

Martin PD, Dane A, Nwose OM, et al. Lack of pharmacokinetic interaction between rosuvastatin and fenofibrate in healthy volunteers. Pharmacol Toxicol 2001; 89 Suppl. 1: Abstract no. 298

33.

Olsson A, Southworth H, WilpshaarJW, et al. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator trial versus atorvastatin. Eur Heart J 2001 Sep; 22 Suppl.: M10333

34.

Davidson M, Ma P, Stein E, et al. Comparison of Effects on Low-Density Lipoprotein Cholesterol and High-Density Li-poprotein Cholesterol With Rosuvastatin versus Atorvastatin in Patients with Type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268–75PubMedCrossRef

35.

Knopp R, Ballantyne C, McPherson R, et al. Comparing rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia. Eur Heart J 2002 Aug; 4: 19

36.

Brown WV, Chitra RR, Zedler BK, et al. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur Heart J 2001 Sep; 22 Suppl.: M10333

37.

Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383–90PubMedCrossRef

38.

Hunninghake DB, Chitra RR, Simonson G, et al. Treatment of hypertriglyceridemic patients with rosuvastatin. Diabetes 2001 Jun; 50 Suppl.2: A143

39.

Durrington P, Hamann A, Tuomilehto J, et al. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia 2001; 44 Suppl.1: A165

40.

Morgan JM, Cressman MD, Hutchinson HG, et al. Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with a mixed dyslipidemia [poster]. XIV International Symposium on Drugs Affecting Lipid Metabolism 2001 Sep 9–12 New York

41.

Hassman D, Berlin NJ, Ballantyne CM, et al. Rosuvastatin lowers non-High-Density lipoprotein cholesterol and apolipoprotein B values compared with atorvastatin, simvastatin and pravastatin. Circulation 2002; 105 (14): Abstract

42.

Marais D, Raal F, Stein E, et al. Effect of Rosuvastatin on LDL-cholesterol, Mevalonic acid, and other lipid measurements in patients with Homozygous Familial Hypercholester-olaemia. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress July 2002 7–10

43.

Stein E, Strutt KL, Miller E. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001 Feb; 37 Suppl. A: 292

44.

Shepherd J, Packard C, Smith K, et al. Evaluation of Rosuvastatin in the Treatment of Hypercholesterolaemia in Postmenopausal Women. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress 2002 July 7–10

45.

Saito Y, Goto Y, Dane A, et al. Randomised, double-blind, placebo-controlled, dose-ranging study of Rosuvastatin in Japanese Hypercholesterolaemic Subjects. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress July 7–10 2002

46.

Wiklund O, Davidson M, Chitra R, et al. Rosuvastatin is more effective than atorvastatin in modifying lipid profiles and achieving National Cholesterol Education Program Adult Treatment Panel III LDL-cholesterol goals. Presented as a poster and abstract at the 73rd European Atherosclerosis Society Congress; 2002 July 7–10; Salzburg, Austria

47.

Strutt K, Caplan R, Hutchinson H, et al. More Western Hypercholesterolaemic patients achieve Japanese Atherosclerosis Society LDL-C targets with rosuvastatin therapy than with atorvastatin therapy. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7–10; Salzburg, Austria

48.

Istad H, Ose L, Stender S, et al. Achievement of the Joint European Societies LDL-cholesterol Goal by hypercholesterolaemic patients receiving rosuvastatin or atorvastatin. Poster and abstract presented at the 73rd European Atherosclerosis Congress; 2002 July 7–10; Salzburg, Austria

49.

Hamilton-Craig I, Schaefer E, Farmer M, et al. Rosvastatin produces significantly greater reductions in low-density lipoprotein cholesterol and more patients achieve treatment goals compared with simvastatin [abstract]. J Am Coll Cardiol 2002 May 1; 39 (9 Suppl. B): 146B

50.

Barter P, Shepherd J, Brown WV, et al. Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin. J Am Coll Cardiol 2002 May 1; 39 (9 Suppl. B): 142B

51.

Paoletti R, Bertolini S, Pisciotta L, et al. Achievement of the Joint European Societies LDL-cholesterol goal by hypercholesterolaemic patients receiving rosuvastatin, pravastatin or simvastatin. Poster and abstract presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7–10; Salzburg, Austria

52.

Olsson A, Pears J, Mckellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001 Sep 1; 88: 504–8PubMedCrossRef

53.

Expert Panel on Detection E and T of high blood cholesterol in A. Summary of the second report of the National Cholesterol Education Program NCEP Expert Panel on Detection,Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015–23CrossRef

54.

Strutt K, Dane A, Blasetto J. More Western hypercholesterolaemic patients achieve Japan Atherosclerosis Society LDL-C targets with rosuvastatin therapy than with pravastatin or simvastatin therapy. Poster presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7–10; Salzburg, Austria

55.

Shepherd J, Carbarns I, Harris S, et al. Safety of Rosuvastatin in patients developing LDL-C <2.07 mmol/L and <1.29 mmol/L in clinical trials. Poster presented at the 73rd European Atherosclerosis Society Congress; 2002 July 7–10; Salzburg, Austria

56.

Shepherd J, Hunninghake D, Harris S, et al. A review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme. Int J Clin Pract 2001; (Suppl. 124)

57.

AstraZeneca. AstraZeneca update on Crestor [online]. Available from URL:http://www.astrazenecacom [Accessed 2002 Aug 15]

Title: Rosuvastatin
Authors: Christopher I. Carswell
Greg L. Plosker
Blair Jarvis
Publication date: 01-10-2002
Publisher: Springer International Publishing
Published in: Drugs / Issue 14/2002
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200262140-00008

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rosuvastatin

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 14/2002

Camptothecins

Valdecoxib

Rosuvastatin

Valdecoxib

Premenopausal Breast Cancer

Polyethylene Glycol-Liposomal Doxorubicin